目的: 探究¹⁸F-氟脱氧葡萄糖正电子发射计算机断层显像(¹⁸F fluorodeoxyglucose positron emission tomography, ¹⁸F-FDG PETCT)代谢参数联合血清人类婆罗双树样基因-4(spalt-like transcription factor 4, SALL4)水平检测对胃癌患者预后的预测价值。方法: 收集2022年4月至2024年1月于本院就诊的59例胃癌患者进行研究,统计59例胃癌患者入院时¹⁸F-FDG PETCT代谢参数、血清SALL4水平,比较不同病理类型患者¹⁸F-FDG PETCT代谢参数、血清SALL4水平,采用Spearman法分析相关性,比较不同预后患者¹⁸F-FDG PETCT代谢参数、血清SALL4水平,分析指标对患者预后的预测价值。结果: 59例胃癌患者SUVmax为7.1(5.07,10.85)、MTV为12.4(6.73,23.15)cm³、TLG为50.8(18.74,187.26)g,其血清SALL4水平为285.7(247.82,312.57)pg/mL;SUVmax、MTV、TLG及血清SALL4水平比较:低分化者＞中、高分化者、Ⅲ～Ⅳ期者＞Ⅰ～Ⅱ期者、有淋巴结转移者＞无淋巴结转移者(P＜0.05);SUVmax、MTV、TLG及血清SALL4水平均与临床分期、淋巴结转移呈正相关(P＜0.05),与分化程度呈负相关(P＜0.05);预后良好者SUVmax、MTV、TLG及血清SALL4水平低于预后不良者(P＜0.05);¹⁸F-FDG PETCT代谢参数、血清SALL4水平联合预测的AUC为0.864,最佳预测敏感度为92.31%,特异度为80.43%。结论: ¹⁸F-FDG PETCT代谢参数、血清SALL4水平均与胃癌患者不同临床病理特征存在密切相关性,可为临床预测胃癌患者预后提供有效参考依据。

Objective: To explore the prognostic value of ¹⁸F fluorodeoxyglucose positron emission computed tomography (¹⁸F-FDG PETCT) metabolic parameters combined with serum spalt-like transcription factor 4 (SALL4) level in patients with gastric cancer. Methods: A study was conducted on 59 gastric cancer patients who visited our hospital from April 2022 to January 2024. The ¹⁸F-FDG PETCT metabolic parameters and serum SALL4 levels of the 59 gastric cancer patients were statistically analyzed upon admission. The ¹⁸F-FDG PETCT metabolic parameters and serum SALL4 level of patients with different pathological types were compared, and the correlation was analyzed using Spearman's method. The metabolic parameters of ¹⁸F-FDG PETCT and serum SALL4 level in patients with different prognosis were compared, and the predictive value of the indicators for the prognosis of patients was analyzed. Results: The SUVmax of 59 patients with gastric cancer was 7.1(5.07,10.85), the MTV was 12.4(6.73,23.15)cm³, the TLG was 50.8(18.74,187.26)g, and the serum SALL4 level was 285.7(247.82,312.57)pg/mL. Comparison of SUVmax, MTV, TLG and serum SALL4 level: low differentiation＞moderate and high differentiation, stage Ⅲ-Ⅳ＞stage Ⅰ-Ⅱ, lymph node metastasis＞no lymph node metastasis (P＜0.05). SUVmax, MTV, TLG and serum SALL4 level were positively correlated with clinical stage and lymph node metastasis (P＜0.05), and negatively correlated with the degree of differentiation (P＜0.05). The levels of SUVmax, MTV, TLG and serum SALL4 in patients with good prognosis were lower than those in patients with poor prognosis (P＜0.05). The AUC of the combined prediction of ¹⁸F-FDG PETCT metabolic parameters and serum SALL4 level was 0.864, the best predictive sensitivity was 92.31%, and the specificity was 80.43%. Conclusion: Both ¹⁸F-FDG PETCT metabolic parameters and serum SALL4 level are closely related to different clinicopathological features of gastric cancer patients, which can provide an effective reference for clinical prediction of prognosis of gastric cancer patients.